Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Must have received: anti-PD-1 therapy — locally advanced or metastatic

Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another systemic therapy.

Cannot have received: platinum-based chemotherapy

Exception: allowed if >12 months since last exposure

must not have platinum-based chemotherapy exposure within 12 months

Cannot have received: antibody-drug conjugate targeting EGFR

must not have prior ADC therapy targeting EGFR

Cannot have received: antibody-drug conjugate targeting HER3

must not have prior ADC therapy targeting HER3

Cannot have received: topoisomerase 1 inhibitor

must not have prior therapy with topoisomerase 1 inhibitor